NLRP3 and type 2 diabetes mellitus: Ye et al. demonstrated that dapagliflozin, an SGLT2 inhibitor, reduced NLRP3/ASC activation in samples of myocardial tissue in mice with T2D, slowing the progression of diabetic cardiomyopathy.